Browsing Tag
Amylin receptor
3 posts
Can Ascletis’ obesity pipeline redefine oral and monthly peptide therapy in 2026?
Find out how Ascletis’ oral and monthly obesity therapies are challenging industry norms with next-gen peptide technology.
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
Iktos and Cube Biotech team up to advance AI-driven drug discovery
Iktos, a leader in artificial intelligence (AI)-powered drug discovery, and Cube Biotech, an innovator in membrane protein technologies,…